Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com -- Teva Pharmaceutical (TADAWUL:2070) Industries (NYSE:TEVA) CEO Richard Francis said on Wednesday the company is well-positioned to handle potential U.S. tariffs despite "big ambiguity" in the drugs sector regarding these measures.
Francis noted that 70% of Teva’s generics business operates outside the United States, while most of its branded drugs business is within the U.S. The company’s largest drug, Huntington’s Disease treatment Austedo, is manufactured in the United States.
Following Teva’s second-quarter earnings release, Francis highlighted the company’s favorable supply chain structure, which includes no reliance on China and very little dependence on India. "Those aspects just set us up in the face of this change, probably a lot better than our competitors," he said.
The CEO expressed confidence in Teva’s position while acknowledging remaining uncertainties, stating, "I feel we have the ability to put ourselves in a good position here, with the caveat - I need to know the details."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.